New more sensitive diagnostics protect transplanted kidney
With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier,...
News | August 29, 2016
Devyser, pioneer in diagnostic kits for complex DNA testing and Sophia Genetics, global leader in data-driven medicine, announce today the signing of a new partnership to simplify the adoption of next-generation DNA sequencing (NGS) for routine diagnostic laboratories. Under the terms of the agreement, Sophia Genetics’ advanced analytical platform, Sophia DDM®, will support Devyser’s NGS diagnostic kits for hereditary breast cancer (Devyser BRCA) and cystic fibrosis (Devyser CFTR).
Ulf Klangby, CEO and co-founder of Devyser, says,
“We are very excited to offer NGS technology that has the capacity to revolutionize genetic testing. This solution will relieve laboratories from the burden of labor-intensive and complex workflows so that they can really focus on diagnostics. Our partnership will help continue to reduce the diagnostic turnaround time from days to hours, enabling laboratories to significantly improve their efficiency and cut costs.”
Jurgi Camblong, CEO and founder of Sophia Genetics, comments:
“We are very pleased to broaden the choice of NGS kits supported by Sophia DDM®. Our fast-growing clinical genomics community will be able to leverage Devyser’s reliable and easy-to-use products to obtain clinical grade results on Sophia DDM®. This partnership continues to help laboratories unlock the power of NGS with record-low turnaround time, improving both diagnostics and treatment options for patients.”
Sophia Genetics’ and Devyser’s joint effort will immediately be launched worldwide to help routine diagnostic laboratories transition to NGS and obtain improved throughput, reduced hands-on time and trusted results. The solutions will be available through Devyser’s distribution network and to the more than 170 member hospitals of the Sophia DDM® clinical genomics community.
With new more sensitive diagnostics, rejection of a transplanted kidney can be detected earlier,...
Read More
Devyser, the pioneering leader in diagnostic solutions, launches today its first IVDR-certified...
Read More
“Further strong organic growth was reported for the year and quarter. Efforts to build an...
Read More
We are pleased to welcome Vertitas Corporation as a new distributor of the Devyser portfolio for...
Read More